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The tumor suppressor p53 is the focus of numerous investigations whose goal is reversing or halting tumor progression. The activity of p53 is tightly regulated in cells through post-translational modifications, localization and degradation 1 . The murine double minute (Mdm2) protein, a product of a p53-inducible gene, is a really interesting new gene (RING)-type E3 ubiquitin ligase responsible for proteasomal degradation of p53 (refs. 2,3) . As an additional regulatory mechanism, Mdm2 binds directly to the first transactivation domain (TAD-I ) of p53, inhibiting its ability to interact with transcriptional coactivators 4 . X-ray crystallography and NMR studies have characterized the interaction between a hydrophobic pocket within the N-terminal region of Mdm2 and a peptide spanning the TAD-I domain of p53 (ref. 5) . Biologically active inhibitors of this interaction (such as Nutlin-3) have been developed with the goal of dissociating p53 from Mdm2 and activating p53 in abnormally proliferating cells [6] [7] [8] .
Upon various forms of DNA damage, the TAD-I of p53 is modified by upstream protein kinases on several residues that weaken its interaction with Mdm2 (refs. 9,10). Nevertheless, biochemical studies show that phosphorylation of the p53 TAD-I is not sufficient to abolish its interaction with Mdm2, suggesting that, in vivo, other determinants are required for full p53 activation [11] [12] [13] . Providing additional complexity, the central acidic domain of Mdm2 interacts with the DNA-binding domain of p53 (within conserved regions IV and V, residues 234-286), and these contacts are essential for proper p53 ubiquitination [14] [15] [16] . Indeed, p53 lacking its TAD-I region is still able to interact with Mdm2 in pulldown experiments and is efficiently ubiquitinated by Mdm2 in vitro 17 .
The key lysines of p53 that are ubiquitinated by Mdm2 reside within its extreme C-terminal 30 residues (p53 CTD) 18 . In addition to ubiquitination, small ubiquitin-like modifier (SUMO), neural precursor cell expressed developmentally downregulated (NEDD8), acetyl groups and methyl groups can also modify the cluster of lysines in the p53 CTD 19 . These modifications are deposited and removed from the ε-NH 3 groups of the lysines by numerous enzymes including the histone acetylase p300, which interacts with the N-terminal domain of p53 (ref. 19) . The ability of Mdm2 to stimulate ubiquitination of the p53 CTD while interacting with distal parts of the protein is still poorly understood, as is the exact mechanism by which RINGtype E3 ligases facilitate ubiquitination of their targets.
Previous studies have alluded to the physical separation of Mdm2 and p53 following C-terminal ubiquitination of p53 (refs. 20,21) . Previous work 21 described monoubiquitination as causal of p53 nuclear export, and other studies 20 expanded on these data to show that Mdm2 dissociates from p53 upon p53 monoubiquitination. This has primarily been shown through changes in the localization of a p53ubiquitin fusion protein from the nucleus to the cytoplasm, although a more recent report showed dissociation between Mdm2-p53 following p53 acetylation 22 . The authors of the above reports acknowledge that the mechanism connecting modifications of the p53 CTD with the release of Mdm2 from the complex remains unclear. Two possibilities emerge: one is that p53 modifications lead to the loss of p53 tetramerization, revealing the nuclear export signal and facilitating export, and the other is that direct contact between Mdm2 and the p53 CTD exists and is regulated by post-translational modifications. Based on results showing that either ubiquitinated or acetylated p53 is competent to activate transcription of p53 target genes, an activity that requires p53 tetramer formation, we chose to pursue an investigation of the latter hypothesis 22, 23 .
Here we present evidence of a direct contact between the C terminus of p53 and the N terminus of Mdm2. Further, we show that the complex between Mdm2 and p53 can be regulated by modifications of the p53 CTD.
RESULTS

The C terminus of p53 contributes to the p53-Mdm2 complex
To investigate the role of the p53 CTD in the interaction with Mdm2, we first looked at the ability of wild-type human p53, p53 with the C-terminal 30 residues deleted (p53 ΔC30) and p53 with the six lysines in the CTD substituted for arginine (p53 6KR) to bind human Mdm2. We expressed these p53 proteins in H1299 stable cell lines ( Fig. 1a and Supplementary Fig. 1a ) and partially purified them on a heparin column, which allows for the isolation of DNA-binding proteins. Because p53 possesses two nucleic acid-binding domains, one at the CTD, the wild-type protein showed higher affinity for heparin than the p53 ΔC30 protein, as expected ( Supplementary Fig. 1b ). We performed pulldown assays with wild-type and variant p53 and Flag-tagged full-length Mdm2 (Fig. 1a) . Wild-type p53 bound Mdm2 better than p53 ΔC30, whereas p53 6KR was only marginally defective. Because of the similar elution profiles from the heparin column of wild-type p53 and p53 6KR ( Supplementary Fig. 1b ), we believe that they have similar overall modifications and thus bind Mdm2 similarly. This is in contrast to previous observations that p53 6KR has higher affinity for endogenous Mdm2 in cells, which was attributed to the protein's inability to become modified 20 .
We assessed the binding of Mdm2 to histidine-tagged p53 and p53 ΔC30 purified from bacteria, in an ELISA. We coated ELISA plates with p53 or p53 ΔC30 (Supplementary Figs. 1c-e ) and measured bound Mdm2 (full-length or a truncation corresponding to its N-terminal domain) with an anti-Mdm2 antibody. Mdm2 bound preferentially to the wild-type p53 ( Fig. 1b) , suggesting that the p53 CTD is needed for full interaction with Mdm2. Notably, we also found that p53 ΔC30 was partially impaired in binding the N terminus of Mdm2 (Fig. 1c) . Therefore, the N-terminal portion of Mdm2 is sufficient to discriminate between full-length and C-terminally truncated p53. Further, these data indicate the existence of a binding site within the N terminus of Mdm2 for the p53 CTD.
Although the p53 CTD is seldom mutated or deleted in tumors 24 , it is a site for multiple modifications, including lysines acetylated by p300 (ref. 19) . We tested whether modifications in p53 CTD decrease binding to Mdm2 using Flag-tagged p53 purified from insect cells that were co-infected with a baculovirus producing p300. p53 coexpressed with p300 is highly acetylated, as shown by a gain of reactivity with a Pan-acetyl antibody and corresponding loss of reactivity with an antibody PAb 421 that recognizes unmodified p53 CTD 372-382 (refs. 25,26) (Supplementary Fig. 2a,b ). We found that acetylated p53 was less able to bind full-length Mdm2 or Mdm2 10-139 compared to wild-type p53 ( Fig. 1d,e ). These results are consistent with a direct interaction between the Mdm2 N terminus and the p53 CTD. It should be noted that, in addition to multiple C-terminal sites, p300 also acetylates p53 at Lys164 in its core domain 22 ; however, this residue is not near the region that makes contacts with the acidic domain of Mdm2 (ref. 25) , indicating that modification of this site should not contribute to the loss of overall binding.
We further probed the interaction of Mdm2 with acetylated p53 using a Fe 2+ -localized hydroxyl radical footprinting assay ( Supplementary Fig. 3 ). The addition of Mdm2 to acetylated or nonacetylated p53 generated a different pattern of cleavage products, with an exclusive cleavage site in unmodified p53. These data suggest that acetylated and nonacetylated p53 bind Mdm2 differently.
The C terminus of p53 interacts with Mdm2
To confirm that the p53 CTD directly binds the Mdm2 N terminus, we performed three distinct binding assays. First, we assayed the binding of GST-Mdm2 10-139 to a p53 CTD 367-397 peptide in a native gel ( Fig. 2a) . The basic p53 CTD peptide (pI ≈ 10.0) does not enter the gel under the buffer conditions we used (pH 8.5) ( Fig. 2a , lanes 9-11). Strikingly, in the presence of GST-Mdm2 10-139 , we were able to detect markedly enhanced migration of the p53 CTD into the native gel (by immunoblotting with PAb 421), consistent with the formation of a complex. The acidic p53 TAD-I 1-42 peptide transverses the gel too rapidly for retention without Mdm2 but was retained in the gel in the presence of Mdm2 ( Fig. 2a , lanes 2 and 6-8). Further, the p53 CTD 367-393 bound Mdm2 even in the presence of p53 TAD-I peptide, suggesting that the two regions of p53 bind the N terminus of Mdm2 noncompetitively ( Fig. 2a a r t i c l e s changes the behavior of the p53 peptides in this assay. Note that, in this assay, neither the CTD nor the TAD peptides appear at the migration position of Mdm2. The fact that the two peptides appear in different positions on the gel is a reflection of their overall charge and not of the binding to two different pools of Mdm2.
Second, we measured the association of a p53 CTD 367-393 peptide with Mdm2 10-139 in a quantitative ELISA ( Fig. 2b) . We also detected binding of the CTD peptide to full-length Mdm2 in a parallel ELISA ( Supplementary  Fig. 4 ). The interpretation of these data, however, is complicated by the potential contribution of nonspecific interaction of the basic CTD peptide with the acidic domain of Mdm2. Additionally, we used a slightly longer histidine-tagged p53 361-393 peptide in the ELISA experiments along with a histidine-tagged NF-κB 303-322 peptide of similar length, which is also very basic (pI ≈ 9.77) ( Fig. 2c) . The basic NF-κB peptide did not show binding Mdm2 above background. Fitting the curve to a binding equation with a Hill coefficient of ~2, we calculated the K d from four independent experiments to be ~30 μM for the binding between the p53 CTD and the N terminus of Mdm2. The addition of the tetramerization domain p53 293-393 markedly improved the binding of p53 to the Mdm2 N terminus in similar ELISA experiments (Fig. 2d) . The calculated K d was ~1 μM. Note that data in Figure 2d is shown following background subtraction to clearly demonstrate binding saturation. In all, we detected the binding of Mdm2 10-139 and three different versions of the p53 CTD by three different antibodies, revealing a specific interaction with binding affinities in the low micromolar range.
As a third approach, we measured Mdm2 interaction with the p53 CTD using fluorescence anisotropy. We compared the binding of GST alone or of GST-Mdm2 10-139 to the fluorescein-labeled p53 367-393 peptide with the binding of GST-Mdm2 10-139 to a fluorescein-labeled NF-κB 303-322 peptide. Only GST-Mdm2 and fluorescein-labeled p53 367-393 binding produced a rounded curve characteristic of specific binding ( Fig. 2e) . GST protein, when incubated with increasing amounts of p53 CTD, did not show such a binding curve. Similarly, GST-Mdm2 protein did not show any measurable affinity for the basic fluorescein-labeled NF-κB 303-322 peptide. The inability of GST-Mdm2 to bind the basic NF-κB peptide (pI ≈ 10) is particularly notable because the binding of the p53 CTD with the N terminus of Mdm2 is electrostatic in nature. The affinity of GST-Mdm2 for the p53 367-393 peptide was reduced when we increased the ionic strength of the buffer from 50 to 100 mM NaCl (Fig. 2f) . This result implies that the p53 CTD is unlikely to interact with the hydrophobic pocket of Mdm2 and thus would not compete for the binding to the N terminus of Mdm2 with the TAD-I domain of p53. We also used fluorescence anisotropy to confirm that the GST-Mdm2 10-139 and Mdm2 10-139 proteins used in the majority of our biochemical assays are properly folded by measuring their binding to the p53 TAD-I peptide. In both cases, we obtained K d values in the nanomolar range, consistent with previously published data ( Supplementary Fig. 5 ).
As an additional specificity control, we performed a competition fluorescence anisotropy experiment. We titrated increasing amounts a d e b c of unlabeled p53 367-393 into a preformed complex of GST-Mdm2 and fluorescein-labeled p53 367-393 at an ionic strength of 50 mM NaCl (Fig. 2g) . The decrease in anisotropy back to the initial values suggests efficient competition.
Mapping the Mdm2-p53 CTD interaction
We next performed formaldehyde and glutaraldehyde cross-linking experiments as an additional test of binding. Here we subjected 8 μM Mdm2 10-139 to glutaraldehyde cross-linking alone or in the presence of 35 μM p53 TAD-I, p53 CTD or p53 nuclear localization signal-I (NLS-I) peptides (Fig. 3a) . Cross-linking resulted in the appearance of novel bands, upshifted by about 5 and 3 KDa in the TAD-I and CTD samples, respectively. The decrease in mobility corresponded to the added molecular weight of the peptide. We also used a p53 305-322 NLS-I peptide that spans a similarly basic region of p53 (pI = 11.3). The intensity of the cross-linked bands corresponds to the probability of cross-link, which is dependent on the number of lysines in each peptide. The p53 TAD-I peptide with only one lysine would cross-link less efficiently than the CTD peptide that has six lysines. However, the fact that p53 TAD-I was cross-linked with much higher efficiency than the p53 NLS-I peptide that contains four lysines serves as a specificity control. We then performed preparative cross-linking experiments using 1% (w/v) formaldehyde 26 . We excised the bands corresponding to Mdm2 and potentially the Mdm2-p53 367-393 crosslinked heterodimer and subjected them to trypsin digestion and MALDI-TOF analysis (Fig. 3b) . For the Mdm2-only band (circled in Fig. 3b , lane 1), masses of at least 13 peptides were matched by Mascot at 22 p.p.m. r.m.s. deviation (68 peptides were searched) with a Mascot score of 111. For the band with putative Mdm2 and p53 (circled in Fig. 3b, lane 3) , we detected Mdm2 with a Mascot score of 75 (12 peptides matched out of 96 peptides searched). Masses of 670.34 and 763.41 m/z support the presence of peptides WSHLK and KGQSTSR, respectively, from p53 in this gel band (Fig. 3c) . Furthermore, formaldehyde cross-linking in this band resulted in the loss of a monoisotopic mass (3, 167 .71 m/z) corresponding to peptide GSMTDGAVTTSQIPASEQETLVRPKPLLLK (residues 10-36 of Mdm2) and a monoisotopic peak at 3,183.70 m/z corresponding to the same mass with oxidized methionine (Fig. 3d,e) . The loss of this peptide suggests that it spans a potential site of the interaction between the p53 CTD and Mdm2.
Mdm2 inhibition of p53 DNA binding requires the p53 C terminus
The p53 CTD has multiple roles in p53 function, serving as a regulatory region and as a non-sequence-specific nucleic acid-interacting domain 27 . If Mdm2 is indeed making contacts with this part of p53, it could also alter the ability of p53 to interact with DNA. To test this hypothesis, we first looked at the binding of heparin-purified p53, p53 ΔC30 or p53 6KR as well as bacterial p53 and p53 ΔC30 to a p53 response element from the p21 promoter in an EMSA. Mdm2 was able to inhibit the p53-DNA interaction in a matter that depended on the presence of the intact CTD (Fig. 4a,b) . Further, the ability of Mdm2 to inhibit p53-DNA interactions was alleviated by the addition of PAb 421 (Supplementary Fig. 6 ). As we previously showed that the off-rate kinetics of p53 and p53 ΔC30 are very similar 28 , we believe that the observed changes in p53-DNA association are caused by interaction with Mdm2. In addition to the loss of p53-DNA complex, we detected a small upward shift of the p53 band in the presence of Mdm2, as has been shown previously 22 . The RING domain portion of Mdm2, GST-Mdm2 410-491 , did not affect the p53-DNA interaction, supporting the likelihood that functional contacts are being made in the N-terminal region of Mdm2 (Fig. 4b) .
To determine whether Mdm2 can affect p53-DNA interactions in cells, we looked at the ability of transfected p53 to interact with the endogenous p21 promoter in the presence of coexpressed Mdm2 by a chromatin immunoprecipitation (ChIP) assay. Coexpression of p53 with Mdm2 in p53/Mdm2 doubly null mouse embryonic fibroblasts (2KO) reduced p53 promoter association (Fig. 4c, graph) , although the levels of p53 were also reduced as a result of the E3 ubiquitin ligase function of Mdm2 (Fig. 4c, immunoblot) . To coexpress p53 and Mdm2 without p53 degradation, we used an E3-deficient mutant of Mdm2 lacking the last seven residues (Mdm2 ΔC7) 29 . Mdm2 ΔC7 did not degrade p53 but was nevertheless able to reduce p53 association with the p21 promoter ( Fig. 4c) . To establish the role of the p53 CTD in the observed inhibition, we coexpressed p53 or p53 ΔC30 with Mdm2 ΔC7. Due to differences in stability between these two proteins, we transfected different amounts of wild-type p53 DNA and p53 ΔC30 DNA to assure equivalent expression. Reproducing our published data, p53 ΔC30 was less effective than wild-type p53 at DNA binding in cells 30 . Furthermore, in accord with our in vitro DNA binding data, Mdm2 did not affect p53 ΔC30 binding to the p21 promoter ( Fig. 4d) . These data suggest that the interaction of 
Nutlin-3 and TAD-I region of p53 bind Mdm2 N terminus differently
Because multiple contacts contribute to the Mdm2-p53 complex, we wanted to determine the relative contributions of the Mdm2 acidic domain and the p53 CTD to the overall binding. To this end, we tested the ability of Mdm2 and p53 to interact in the presence of Nutlin-3 or p53 TAD-I 1-42 . Both of these reagents have been reported to have nanomolar affinities for Mdm2 and to effectively block complex formation between Mdm2 25-128 and p53 1-312 (refs. 6,31) . Accordingly, Nutlin-3 completely blocked the interaction between Mdm2 10-139 and the p53 TAD-I 1-42 peptide in native gel experiments ( Supplementary  Fig. 7) . In ELISA-dissociation experiments, however, both Nutlin-3 and p53 TAD-I 1-42 peptide inhibited binding between full-length p53 and Mdm2 10-139 with IC 50 values of ~1 μM (Fig. 5a) . Because earlier reported competition studies were performed with p53 lacking its C terminus, we believe that the difference in affinity we observed (nM versus μM IC 50 values) is due to the contribution of the contacts made by the p53 CTD to the Mdm2-p53 complex. Indeed, when testing the ability of Nutlin-3 and the p53 TAD-I 1-42 peptide to block the binding of full-length p53 and full-length Mdm2, we observed a r t i c l e s that the IC 50 for Nutlin-3 was ~10 μM, whereas the TAD-I peptide showed very limited inhibition of the interaction (Fig. 5b) . Based on these data, we postulate that, in vitro, both the core domain of p53 and the p53 CTD make appreciable energetic contributions to the overall complex. This implies that, even when the interaction between the N termini of these proteins is disrupted, additional modification of the acidic domain of Mdm2 and/or the CTD of p53 may be necessary to completely dissociate Mdm2 and p53 in vivo.
We tested at the ability of the p53 CTD 367-393 peptide to interact with Mdm2 10-139 in a native gel alone or in the presence of Nutlin-3 or the p53 TAD-I 1-42 peptide. The addition of the TAD-I 1-42 peptide did not disrupt the p53 CTD 367-393 interaction with Mdm2. Nevertheless, Nutlin-3 reduced the binding between the CTD and Mdm2 in this assay (Fig. 5c) . These data fall in line with an NMR investigation that compared the structures of the Mdm2 N-terminal domain alone, bound to p53 or bound to Nutlin-3 and showed that Nutlin-3 binds Mdm2 via a mechanism distinct from that of p53 (ref. 32 ). Thus, it is possible that Nutlin-3-induced changes, which are perhaps refractory to CTD binding, are further contributing to the in vivo efficacy of this compound.
Nutlin-3 and p14 ARF induce modification of the p53 CTD
Having accumulated a substantial amount of data showing the interaction between the p53 CTD and the N terminus of Mdm2, we were faced with a contradictory issue. In vivo, inhibitors of the binding between the N terminus of p53 and the N terminus of Mdm2 (such as Nutlin-3) are able to effectively stabilize p53 and activate p53 function 8, [33] [34] [35] [36] [37] . Nutlin-3 was reported to cause p53 stabilization without p53 being phosphorylated at several known stress-inducible sites 38 . If Nutlin-3 was able to completely inhibit p53-Mdm2 complex formation without induction of any p53 post-translational modifications, then our in vitro binding data would not be relevant under physiological conditions. However, if the dissociation of the N-terminal binding domains leads to increased C-terminal modifications (such as acetylation) of p53 in vivo, it is possible that Nutlin-3 treatment would not only affect the N-terminal interaction but would also decrease the C-terminal interaction as well.
We treated HCT116 cells with 10 μM Nutlin-3 and, as expected, levels of p53 and Mdm2 increased when detected in whole-cell extracts with a mixture of p53 N-terminal antibodies (PAb 1801 and DO1) and Mdm2 antibodies (SMP14 and 2A10), respectively (Fig. 6a, left, lanes 1  and 2, and right, lanes 3 and 4) . Consistent with the proposed mechanism of action of Nutlin-3, p53 in cells treated with this compound was not able to interact with Mdm2, as we were only able to detect Mdm2 in p53 immunoprecipitates from untreated cells (Fig. 6a, lanes 3 and 4) . Strikingly, when we detected p53 in these cells with modificationsensitive PAb 421, there was no increase in reactivity after Nutlin-3 treatment (Fig. 6a, lanes 1 and 2, and Fig. 6b, lanes 3 and 4) . Ablating Mdm2 by siRNA in these cells also caused an overall p53 accumulation and a decrease in 421-detectable p53, confirming the validity of using PAb 421 reactivity as readout of p53 CTD modifications (Fig. 6b, lanes  1 and 2) . This result correlates with our earlier finding that having excess Mdm2 in cells leads to a decrease in p53 C-terminal acetylation 39 . Using a Pan-acetyl antibody, we saw an increase in signal from p53 after treatment (Fig. 6a) . Thus, Nutlin-3 induces modifications of p53 at the C terminus (including acetylation), and this likely diminishes the interaction of the p53 CTD with Mdm2.
It has been previously reported that p14 ARF expression is able to stabilize p53 in the absence of N-terminal modifications 40 . To test the effects of p14 ARF on the p53 CTD modifications, we used NARF cells 41 . p14 ARF induction led to stabilization of p53 and accumulation of p21 and Mdm2 (Fig. 6c) . We then compared PAb 421 and PAb 1801-DO1 reactivity of p53 in NARF cells. Similarly to Nutlin-3 treatment, the amount of p53 detected by a mixture of PAb 1801-DO1 antibodies increased following p14 ARF induction, whereas PAb 421 reactivity remained unchanged (Fig. 6d, lanes 3-5) . Thus, three distinct DNA damage-independent Mdm2 inhibitors were able to stimulate modifications of p53 CTD, most likely by shifting binding equilibrium away from Mdm2 and toward other modifying enzymes.
DISCUSSION
The interaction of Mdm2 and p53 is a highly regulated fine-tuned process. Here we describe an additional level of modulation of this association. Using different approaches, we show that the p53 CTD interacts directly with the Mdm2 N terminus. C-terminal modifications of p53 can contribute to the full dissociation of Mdm2-p53 complex in vivo, and Nutlin-3 treatment or p14 ARF overexpression can induce C-terminal modifications of p53 in cells. We propose a model where multiple interactions between p53 and MDM2 act in concert for optimal regulation of p53 ( Fig. 7) .
We calculated the binding constant for the Mdm2-p53 CTD complex to be in the low micromolar range, which is similar to the affinity of peptides from the Mdm2 acidic region for p53 core domain (in the range of 10-100 μM (refs. 14-16)) but much weaker than the interaction of Mdm2 with the p53 N terminus (nanomolar range). Although we were unable to obtain evidence for complex formation Fig. 8) , multiple other assays confirmed direct binding, and our data indicate that p53 CTD-Mdm2 interaction is important for overall Mdm2-p53 binding. Indeed, the rather low affinity of the CTD for Mdm2 may actually be essential to allow this interaction to be modulated by modifications of the lysines in this region of the protein.
The interaction between the p53 CTD and Mdm2 described here provides a potential mechanism for published observations linking C-terminal modifications of p53 and the dissociation of the Mdm2-p53 complex 20, 22 . We have only addressed the effects of C-terminal acetylation of p53 on the Mdm2-p53 complex formation; the global regulatory scheme is likely to be far more complex. Mdm2 is extensively phosphorylated within its acidic domain 19, 42, 43 . The interaction of the Mdm2 acidic domain with the box IV and box V regions of p53 is essential for proper p53 ubiquitination by Mdm2 (ref. 14) . Our results that the Mdm2-p53 complex involves multiple contacts are consistent with the observations that the Nutlin-3 and TAD-I peptides or the removal of the 116 N-terminal residues of p53 do not block the ability of Mdm2 to ubiquitinate p53 in vitro 15, 17 . It would be exciting to investigate effects of posttranslational modifications of Mdm2 and p53 from the perspective of their ability to stimulate or inhibit the formation of the multiple Mdm2/p53 interfaces.
The data (see Figs. 2a and 5c) showing that the binding of p53 CTD and TAD-I domains to Mdm2 are not mutually exclusive presuppose that different surfaces within the Mdm2 N terminus contact the TAD-I and p53 CTD. Indeed, our preliminary MALDI-TOF analysis suggests that the p53 CTD interacts with the flexible lid region at the N terminus of Mdm2. This is of considerable interest, as apo Mdm2 predominantly exists in the closed conformation, which disfavors p53 interaction 32, 44 . Potentially, binding of the basic p53 CTD to this region would disrupt the intramolecular contacts made by the lid region and facilitate the conversion of Mdm2 to an open conformation, thereby stimulating the binding of the TAD-I domain. Our findings also predict that the N and C termini of p53 are in spatial proximity, at least while both are bound to Mdm2. The putative closeness of the N and C termini of p53 in the context of the intact p53 tetramer could provide additional mechanisms of p53 regulation and could facilitate Mdm2-mediated ubiquitination of this region. Perhaps modifications of the p53 CTD disrupt contacts not only with Mdm2 but alter the spatial relationship between the TAD-I and the p53 CTD, causing long-range conformational changes in the overall protein structure. Such changes could contribute to the loss of Mdm2 binding and could have other functional consequences for p53-mediated transcription.
Nutlin-3 activates p53 efficiently in vivo. Based on our data, we propose that multiple cooperating factors are needed for a robust p53 response. According to our model, Nutlin-3 disrupts the N terminus of p53 from binding Mdm2, thus freeing the p53 N terminus to bind other C-terminal modifiers such as p300 (refs. 45,46) . Consequent modifications of the p53 C terminus further destabilize the Mdm2-p53 complex. Thus, Nutlin-3 treatment shifts the competition between positive and negative regulators of p53 toward the positive regulators 19, 47 (Fig. 7) . Both Nutlin-3 treatment and p14 ARF expression lead to accumulation of p53 protein that lacks DNA damage-inducible phosphorylation marks at multiple N-terminal sites 38, 40 . In this light, the induction of C-terminal modifications by both of these pathways seems highly noteworthy, as such modifications could dictate differential transcriptional programs and could lead to varying outcomes depending on cellular context. It has been reported that phosphorylation of p53 at key N-terminal residues induces association with p300, leading to C-terminal modification 48, 49 . However, unphosphorylated p53 is still able to bind p300, and we believe that this interaction would be favored in cells where Mdm2 is either sequestered in complex with p14 ARF or inhibited by Nutlin-3. Additionally, it is possible that Nutlin-3 and other p53activating compounds are more effective in cancer cells 6,8 -these cells may already have a low level of stress-induced modifications on p53 (refs. 50,51) , so the dissociation of Mdm2 and p53 would be accomplished more easily in such cells.
Finally, our finding of a third interface between p53 and Mdm2 allows for a more detailed view of the complex and could provide additional avenues for therapeutic activation of wild-type p53 in cells.
METhODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/nsmb/. Figure 7 Proposed mechanism for the function of the p53 C terminus and its modifications in Mdm2 complex formation. Model postulates interactions between three p53 and three Mdm2 regions. Within the N-terminal ~140 residues of Mdm2 are predicted to be two discrete surfaces that interact with the N and C termini of p53, respectively; the third interacting surfaces are within the central regions of p53 (core domain) and Mdm2 (the acidic region). Modifications at the N terminus of p53 or disruption of its contacts with Mdm2 in vivo facilitate further modifications at the C terminus, leading to full disruption of the complex. Alternatively, modification(s) within the C terminus of p53 could destabilize the Mdm2-p53 complex, favoring its dissociation. 
